Compare · ANIP vs MRK
ANIP vs MRK
Side-by-side comparison of ANI Pharmaceuticals Inc. (ANIP) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANIP and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $285.22B, about 157.6x ANIP ($1.81B).
- Over the past year, ANIP is up 25.6% and MRK is up 49.3% - MRK leads by 23.6 points.
- MRK has been more active in the news (19 items in the past 4 weeks vs 7 for ANIP).
- MRK has more recent analyst coverage (25 ratings vs 11 for ANIP).
- Company
- ANI Pharmaceuticals Inc.
- Merck & Company Inc.
- Price
- $82.90+2.92%
- $119.59+3.59%
- Market cap
- $1.81B
- $285.22B
- 1M return
- +0.27%
- +3.21%
- 1Y return
- +25.63%
- +49.25%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 7
- 19
- Recent ratings
- 11
- 25
ANI Pharmaceuticals Inc.
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest ANIP
- SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $41,015 worth of shares (500 units at $82.03) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 77,890 units (SEC Form 4)
- Director Thoma Jeanne was granted 4,357 shares, increasing direct ownership by 19% to 27,762 units (SEC Form 4)
- Director Tannenbaum Renee P was granted 4,357 shares, increasing direct ownership by 17% to 29,514 units (SEC Form 4)
- Director Pera Antonio R was granted 4,357 shares, increasing direct ownership by 19% to 27,017 units (SEC Form 4)
- Director Leonard Matthew J was granted 4,357 shares, increasing direct ownership by 63% to 11,221 units (SEC Form 4)
- Director Haughey Thomas was granted 4,357 shares and sold $161,760 worth of shares (2,000 units at $80.88) as part of a pre-agreed trading plan, increasing direct ownership by 6% to 38,878 units (SEC Form 4)
- SVP & CFO Carey Stephen P. exercised 3,312 shares at a strike of $49.51 and sold $264,960 worth of shares (3,312 units at $80.00) as part of a pre-agreed trading plan (SEC Form 4)
- ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
- ANI Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Walsh Patrick D sold $1,127,120 worth of shares (13,973 units at $80.66), decreasing direct ownership by 27% to 38,432 units (SEC Form 4)
Latest MRK
- U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
- Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
- Merck Animal Health to Acquire TARGAN
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
- SEC Form 4 filed by Director Warden Kathy J
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- SEC Form 4 filed by Director Thulin Inge G
- SEC Form 4 filed by Director Seidman Christine E